Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.

BMC cancer - 23 Jun 2020

Mäkelä Rami, Arjonen Antti, Härmä Ville, Rintanen Nina, Paasonen Lauri, Paprotka Tobias, Rönsch Kerstin, Kuopio Teijo, Kononen Juha, Rantala Juha K

Abstract excerpt

BACKGROUND: Ex vivo drug screening refers to the out-of-body assessment of drug efficacy in patient derived vital tumor cells. The purpose of these methods is to enable functional testing of patient specific efficacy of anti-cancer therapeutics and personalized treatment strategies. Such approaches could prove powerful especially in context of rare cancers for which demonstration of novel therapies is difficult...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Screening Assays, Antitumor
Share to Enzyme Assays

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Feasibility Studies

Share to Mitogen-Activated Protein Kinase Kinases

Share to Primary Cell Culture

Share to Proto-Oncogene Proteins c-met

Share to TOR Serine-Threonine Kinases

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32576176
DOI: 10.1186/s12885-020-07092-w
PMCID: PMC7313172

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.PMID 32576176Read ↗

Guidance of adjuvant instillation in intermediate risk non- muscle invasive bladder cancer by drug screens in patient derived organoids. A Single center, Open-label, Phase II trial. GAIN-INST-TrialSemantic proximity Read ↗

From 2D Drug Screening to Predictive Pharmacology: Redefining Preclinical Models in OncologySemantic proximity Read ↗

Patient‐Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug ScreeningSemantic proximity Read ↗

Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancerSemantic proximity Read ↗

In vitro drug testing using patient-derived ovarian cancer organoidsSemantic proximity Read ↗

Individual patient oesophageal cancer 3D models for tailored treatment.Semantic proximity Read ↗

High-Content Monitoring of Drug Effects in a 3D Spheroid ModelSemantic proximity Read ↗

Ex vivo assessment of targeted therapies in a rare metastatic epithelial-myoepithelial carcinoma.Semantic proximity Read ↗

Assessing Radiosensitivity of Bladder Cancer in vitro: A 2D vs. 3D ApproachSemantic proximity Read ↗

Innovative In Vitro-In Silico Platform for Dose-Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based ApproachSemantic proximity Read ↗

Continuous culture of urine-derived bladder cancer cells for precision medicineSemantic proximity Read ↗

Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.